本文采用随机、双盲、安慰剂对照交叉试验，评价了吉非贝齐（gemfibrozil）治疗原发性低度高密度脂蛋白胆固醇（HDL－C）的疗效。14例HDL－C低度患者，接受国家胆固醇二步饮食教育程序，随机分构使用安慰剂组和吉非贝齐组，每组观察3个月，在H次观察期间休息1个月。结果表明， This randomized, double-blind, placebo-controlled crossover trial evaluated the efficacy of gemfibrozil in the treatment of primary low-density lipoprotein cholesterol (HDL-C). Fourteen patients with low HDL-C were enrolled in the National Cholesterol Two-Step Diet Education Program. Patients in the placebo group and the gemfibrozil group were randomized to 3 months of observation and 1 month of rest in each of the H observations. The results show,